New emerging applications of molgramostim in acute myeloid leukaemia.
Xavier Thomas
Index: Expert Opin. Drug Metab. Toxicol. 4(6) , 795-806, (2008)
Full Text: HTML
Abstract
Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the proliferation and differentiation of hematopoietic progenitor cells in the myeloid lineage, and plays a key role in host defence and the inflammatory process. The main schedules adopted for clinical applications of GM-CSF in acute myeloid leukaemia (AML) were post-chemotherapy, in order to shorten the duration of neutropenia, and as a mobilising agent to induce release of progenitor cells from bone marrow into circulation.
Related Compounds
Related Articles:
2012-01-01
[J. Asian Nat. Prod. Res. 14(9) , 877-85, (2012)]
2012-01-01
[Int. J. Artif. Organs 35(1) , 67-76, (2012)]
Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
2000-01-01
[Pflugers Arch. 440(5 Suppl) , R81-2, (2000)]
Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients.
2000-10-01
[Cytokine 12(10) , 1570-4, (2000)]
2005-06-01
[Can. J. Surg. 48(3) , 213-8, (2005)]